Paragangliomas of the urinary bladder: A report of 6 cases and review of the literature  by Chang, Yi-Kai et al.
lable at ScienceDirect
Urological Science 26 (2015) 111e114Contents lists avaiUrological Science
journal homepage: www.urol-sci .comOriginal articleParagangliomas of the urinary bladder: A report of 6 cases and review
of the literature
Yi-Kai Chang, I-Ni Chiang, Chung-Hsin Chen, Shuo-Meng Wang, Yuan-Ju Lee,
Yeong-Shiau Pu, Chao-Yuan Huang*
Department of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taiwana r t i c l e i n f o
Article history:
Received 1 May 2014
Received in revised form
6 May 2015
Accepted 18 May 2015
Available online 18 June 2015
Keywords:
bladder tumor
paragangliomas
treatment
diagnosis
prognosis* Corresponding author. Department of Urology,
Hospital, College of Medicine, National Taiwan Univers
Road, Taipei City 100, Taiwan. Tel.: þ886 2 2312 3456
E-mail address: cyhuang0909@ntu.edu.tw (C.-Y. H
http://dx.doi.org/10.1016/j.urols.2015.05.005
1879-5226/Copyright © 2015, Taiwan Urological Assoa b s t r a c t
Objective: Extra-adrenal pheochromocytomas are known as paragangliomas. The majority of extra-
adrenal tumors occur intra-abdominally along the sympathetic chain. However, they may also occur in
the urinary tract, including the urinary bladder.
Materials and methods: In this study, we report a clinical series of six patients diagnosed with bladder
paragangliomas in our hospital over the past two decades, and review the literature regarding this
unusual disease.
Results: Among the six cases, two were male and four were female. The most common presentation was
painless gross hematuria, with ﬁve of the six patients (83.3%) having this chief complaint. Two patients
presented with hypertension and one with palpitations. Two had malignant bladder paragangliomas,
and one died within one year after the diagnosis. Four patients received transurethral resection of the
bladder tumors, and one patient developed tumor recurrence within one year of follow-up.
Conclusion: Bladder paraganglioma is an extremely rare tumor with a high recurrence rate, and the most
common presenting symptom in our series was painless gross hematuria. Large, polypoid, and multiple
tumors indicate malignancy.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Pheochromocytomas are catecholamine-secreting tumors
derived from adrenal glands and the sympathetic nervous system.
Extra-adrenal pheochromocytomas, known as paragangliomas,
account for about 15% of all pheochromocytomas1. Bladder para-
gangliomas are extremely rare, accounting for less than 0.06% of all
bladder tumors and less than 1% of all pheochromocytomas.1e3 The
most common symptoms of bladder paragangliomas are hyper-
tension, headache, hematuria and palpitations, with characteristic
micturition attacks, i.e., secretion of catecholamines causing
paroxysmal hypertension, palpitations, and micturition syncope.3
These tumors are typically benign, however, approximately 10%
possess the capacity to invade and thus are deemedmalignant even
though they lack mitoses and cellular dissociation that are usually
associated with malignant tumors. However, only when theNational Taiwan University
ity, 11F., No. 7, Chung-Shan S.
x65238.
uang).
ciation. Published by Elsevier Taiwprimary tumor inﬁltrates locally into the non-nervous system or
grows in organs without embryo residual ganglia such as the liver,
spleen, lungs, brain, bones, and lymph nodes, can the diagnosis of
malignant paraganglioma be made.1 Herein, we present a series of
six cases with bladder paragangliomas, and describe the clinical
presentations, surgical interventions, pathological reports, and
clinical outcomes. We also review the literature to provide more
information and understanding of this rare disease.
2. Materials and methods
We retrospectively reviewed the pathological and clinical data-
base of the National Taiwan University Hospital by International
Classiﬁcation of Diseases (ICD-9) code for the past 25 years. Six cases
of bladder paragangliomaswere identiﬁed.Wepresent the patients'
characteristics, initial clinical presentations, treatment courses,
post-operative pathological reports, recurrence, and survival.
3. Results
Among the six cases of bladder paragangliomas, four were fe-
male and two were male with an average age of 52.6 years (rangean LLC. Open access under CC BY-NC-ND license.
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Table 1. The most common presenting symptomwas painless gross
hematuria (5/6). Hypertension was noted in one-third of the pa-
tients, and one patient suffered from palpitations. The character-
istic micturition attack occurred in only one patient with
palpitations and headache during voiding.
Two patients received partial cystectomy for large tumors with
the pathological results showing malignant bladder para-
ganglioma. Case number 1 was a 21-year-old male, who presented
with multiple, large, polypoid malignant bladder paragangliomas
with tumor invasion to extra-vesical fat tissue. He initially under-
went partial cystectomy for suspected extra-vesical tumor exten-
sion, and since then he has received regular cystoscopy, annual
urine/plasma Vanillomandelic acid (VMA) examinations (Figure 3),
and abdominal/pelvic magnetic resonance imaging follow-up for
ten years and six months to date. Twenty-four-hour urine VMA
showed a dramatic drop in VMA level after the partial cystectomy
until now. He is still well without recurrence. Case number 2 was a
53-year-old female patient with concurrent, multiple, large,
polypoid malignant bladder paragangliomas with invasion to the
uterus, vagina and bilateral ovaries. She underwent partial cys-
tectomy, total hysterectomy and bilateral salpingo-oophorectomy.
However, the post-operative course was complicated with ves-
icovaginal ﬁstula which developed three months after radical sur-
gery, and she died 21 months after the diagnosis of the disease. The
death cause was urosepsis. No adjuvant therapy was given.
The other four patients received transurethral resection of the
bladder tumor (TUR-BT) for small bladder paragangliomas. One of
them was a 68-year-old male patient who was diagnosed with a
bladder tumor incidentally while undergoing transurethral resec-
tion of the prostate (TUR-P). He received TUR-BT, and the pathology
revealed a benign bladder paraganglioma (Table 1, case number 6).
Post-operative follow-up computed tomography one year after the
operation revealed one intra-mural tumor (Figure 1a and 1b). He
received a second TUR-BT (Figure 2) and the pathology also showed
paraganglioma of the bladder. The other three patients underwent
TUR-BT with a smooth recovery course and no evidence of recur-
rence. These patients were all noted with normal blood pressure
post-operatively.
The specimens of the two malignant bladder paragangliomas
(Case 1 and 2) were large polypoid tumors, both rich in blood
supply and broad-based. The specimens of the four benign para-
gangliomas (Case 3 to 6) were round or ovoid tumors. Only one
patient had pre-operative and post-operative VMA/catecholamine
data. The 21 year-old male was noted with early onset of hyper-
tension with elevated urine norepinephrine 1009ug/24hr and
elevated urine VMA 16.8mg/24hr pre-opearatively. Post-operative
urine norepinephrine and VMA were 4.3ug/24hr and 3.8ng/24hr.
Signiﬁcantly decreased urine norepinephrine and VMAwere noted
after partial cystectomy. In the pathology reports of our patients,
we noted positive s-100, positive chomogranin, positiveTable 1
Clinical characteristics of 6 patients with bladder paraganglioma.
Case Sex/Age Presentation Tumor appeara
Hematuria HTN Palpitation Micturition
attack
1 M/21y þ þ þ þ Multiple, large,
polypoid
2 F/53y þ þ   Multiple, large,
polypoid
3 F/59y þ    Single, small, o
4 F/59y þ    Single, ovoid
5 F/56y þ    Single, round
6 M/68y     Single, roundsynaptophysis and negative cytokeratin. Vimentin was not specif-
ically stained by our pathologists.
4. Discussion
Pheochromocytomas are derived from the adrenal gland, and
extra-adrenal pheochromocytomas are named paragangliomas,
which account for 15e20% of all paragangliomas. Paragangliomas
can occur anywhere from the head and neck to the pelvic region.
Paragangliomas have also been reported in peri-renal and prostate
glands in the genitourinary systems.2 Dana et al. reported 236
extra-adrenal benign paragangliomas, and only two originated
from the bladder. Bladder paraganglioma is a rare tumor that was
ﬁrst described by Zimmerman in 1953.3 The incidence of bladder
paraganglioma is less than 0.06% of all bladder tumors and less than
1% of all pheochromocytomas. Some of these tumors display
functional characteristics and properties, such as normal urine or
serum epinephrine levels, unlike pheochromocytomas, due to a
lack of phenylethanolamine N-methyltransferase, the converting
enzyme from norepinephrine to epinephrine. The most common
presentations are painless gross hematuria and hypertension,
headaches, and palpitations.
Our ﬁndings revealed a trend of female and middle-age pre-
dominance, which is compatible with previous studies.4e6 Our re-
sults also share some common unique characteristics of bladder
paragangliomas described by previous articles. First, the most
common presenting symptomwas painless gross hematuria,7,8 and
the supposedly characteristic micturition attack was only observed
in 16.6% of our patients, which is consistent with previous
studies.7,9 The most well-known pathological ﬁnding refers to the
“Zellballen” pattern, in which immunohistochemical staining is
usually positive for synaptophysin and chromogranin, with S-100
being highlighted in sustentacular cells (Figure 4).
The diagnosis of primary, malignant, non-urothelial bladder
tumor has been deﬁned by WHO.10 Bladder paraganglioma is an
extraadrenal tumor of neural crest derivation that classically
demonstrates groups of fairly uniform, polygonal cells (Zell-
ballen).11 With WHO criteria, paragangliomas are deﬁned as ma-
lignant or benign in consideration of invasion of adjacent tissues
and metastasis. It is controversial to diagnose and to predict ma-
lignant behavior in paraganglioma with histopathologic charac-
teristics and scoring system.12 In a previous case report and
literature review, immunohistochemical staining for chromogra-
nin, synaptophysin, and CD 56 were positive.13
More than 180 cases of bladder paragangliomas were reported
before 2007, less than 30 of which were malignant.14 However,
there are no deﬁnite pathological criteria for malignancy at present,
and only the clinical behavior can distinguish benign cases from
malignant cases. In our experience, large, multiple, polypoid and
broad-based tumors are more likely to be malignant, while small,
single, round or ovoid tumors are more likely to be benign. Dengnce Management Pathology Follow-up
(mo)
Outcome
TUR-BT, partial
cystectomy
Malignant
paraganglioma
122 No recurrence
Partial cystectomy,
ATH and BSO
Malignant
paraganglioma
28 Died
void TUR-BT Paraganglioma 60 No recurrence
TUR-BT Paraganglioma 89 No recurrence
TUR-BT Paraganglioma 26 No recurrence
TUR-BT Paraganglioma 19 Bladder recurrence
Figure 1. A 68-year-old male received TUR-BT for bladder paraganglioma, and a follow-up CT scan 1 year post-operatively showed recurrence of the bladder paraganglioma in the
right lateral wall (arrow), with no extra-vesical invasion.
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surface and pelvic lymphadenopathy are the major characteristics
for malignant bladder paragangliomas.4 Not all the patients
received MRI. Most of them were noted with incidentally found
bladder tumors due to hematuria. And most of them received
abdominal and pelvic CT due to bladder tumor noted by cystoscopy.
Many experts advocate complete surgical removal as the stan-
dard management for paragangliomas, including partial cys-
tectomy or radical cystectomy.4,5,7,9 It is believed that
paragangliomas of the bladder originate from the intra-mural
portion of the bladder wall, and that it is therefore difﬁcult to
remove the tumor entirely with TUR-BT only. Furthermore, TUR-BT
may result in ﬂuctuation of blood pressure either with irrigation of
distilled water or saline intra-operatively, or electrical stimulation
during resection and cauterization.15,16
However, some surgeons still perform TUR-BT and follow the
patients regularly for small tumors at special tumor locations. The
advantage of a minimally invasive modality is a shorter recoveryFigure 2. The second cystoscopic ﬁnding of the 68-year-old male after the CT scan
revealing tumor recurrence. One ovoid tumor, slightly protruding from the submucosa
area, was noted. The second pathology was still bladder paraganglioma.period.17 According to a previous case series, bladder para-
ganglioma is a tumor with a high recurrence rate regardless of the
treatment modality.9 Deng et al described one of three patients
with a benign bladder paraganglioma which recurred after TUR-BT
despite the small tumor size.4 This is similar to the 68 year-oldmale
patient in our series who had tumor recurrence one year after TUR-
BT. These two cases highlight the high recurrence rate even for
small-sized, benign tumors, so once the diagnosis of bladder par-
aganglioma has been made, a much more extensive treatment
modality such as partial or radical cystectomy should be preferred.
Complete removal of the total tumor mass is optimal, however for
small tumors or peri-ureteral oriﬁce lesions, TUR-BT with regular
computed tomography and urine VMA follow-up is another treat-
ment option.
Tsai et al. suggested that post-operative follow-up protocols
should include annual cystoscopy, plasma or urine catecholamine
analysis and an 131I-MIBG scan.17e19 Young et al regarded annualFigure 3. A 21-year-old male patient with malignant bladder paraganglioma. He
received initial TUR-BT and partial cystectomy for the large tumor and extra-vesical
invasion. He received regular annual 24-hour urine VMA tests which revealed no
elevation post-operatively.
Figure 4. The pathology specimen of benign bladder paraganglioma of a 56-year-old
female. She was diagnosed with a bladder tumor due to gross hematuria. The specimen
was positive for synaptophysin (40) and it showed the Zeballen pattern.
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recurrence or distant metastasis.20 Life-long follow-up is necessary
to detect late recurrences as suggested in previous studies.215. Conclusion
In summary, we report the high recurrence rate of bladder para-
ganglioma, even with benign or small tumors. If bladder para-
ganglioma is diagnosed, especially with a large tumor size, partial or
radical cystectomywith life-long follow-up is strongly recommended.Conﬂicts of interest
All contributing authors declare no conﬂicts of interest.Sources of Funding
No funding was received for the work described in the article.References
1. Zhou M, Epstein JI, Young RH. Paraganglioma of the urinary bladder: a lesion
that may be misdiagnosed as urothelial carcinoma in transurethral resection
specimens. AJSP 2004;28:94e100.
2. Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, van Heerden JA,
et al. Benign paragangliomas: clinical presentation and treatment outcomes in
236 patients. J Clin Endocrinol Metab 2001;86:5210e6.
3. Zimmerman IJ, Biron RE, Macmahon HE. Pheochromocytoma of the urinary
bladder. N Engl J Med 1953;249:25e6.
4. Deng JH, Li HZ, Zhang YS, Liu GH. Functional paragangliomas of the urinary
bladder: a report of 9 cases. Chin J Cancer 2010;29:729e34.
5. Cheng L, Leibovich BC, Cheville JC, Ramnani DM, Sebo TJ, Neumann RM, et al.
Paraganglioma of the urinary bladder: can biologic potential be predicted?
Cancer 2000;88:844e52.
6. Piedrola G, Lopez E, Rueda MD, Lopez R, Serrano J, Sancho M. Malignant
pheochromocytoma of the bladder: current controversies. Eur Urol 1997;31:
122e5.
7. Leestma JE, Price Jr EB. Paraganglioma of the urinary bladder. Cancer 1971;28:
1063e73.
8. Das S, Bulusu NV, Lowe P. Primary vesical pheochromocytoma. Urology
1983;21:20e5.
9. Tsai CC, Wu WJ, Chueh KS, Li WM, Huang CH, Wu CC, et al. Paraganglioma of
the urinary bladder ﬁrst presented by bladder bloody tamponade: two case
reports and review of the literatures. Kaohsiung J Med Sci 2011;27:108e13.
10. Montironi R, Mazzucchelli R, Scarpelli M, Lopez-Beltran A, Cheng L. Morpho-
logical diagnosis of urothelial neoplasms. J Clin Pathol 2008;61:3e10.
11. Dahm P, Gschwend JE. Malignant non-urothelial neoplasms of the urinary
bladder: a review. Eur Urol 2003;44:672e81.
12. Mlika M, Kourda N, Zorgati MM, Bahri S, Ben Ammar S, Zermani R. Prognostic
value of Pheochromocytoma of the Adrenal Gland Scaled Score (Pass score)
tests to separate benign from malignant neoplasms. La Tunisie medicale
2013;91:209e15.
13. Quist EE, Javadzadeh BM, Johannesen E, Johansson SL, Lele SM, Kozel JA. Ma-
lignant paraganglioma of the bladder: a case report and review of the litera-
ture. Pathol Res Pract 2015;211:183e8.
14. Kairi-Vassilatou E, Argeitis J, Nika H, Grapsa D, Smyrniotis V, Kondi-Paﬁti A.
Malignant paraganglioma of the urinary bladder in a 44-year-old female:
clinicopathological and immunohistochemical study of a rare entity and
literature review. Eur J Gynaecol Oncol 2007;28:149e51.
15. Liu Y, Dong SG, Dong Z, Mao X, Shi XY. Diagnosis and treatment of pheo-
chromocytoma in urinary bladder. J Zhejiang Univ Sci B 2007;8:435e8.
16. Vyas S, Kalra N, Singh SK, Agarwal MM, Mandal AK, Khandelwal N. Pheo-
chromocytoma of urinary bladder. Indian J Nephrol 2011;21:198e200.
17. Wei-Kung Tsai SY. Bladder pheochromocytoma: a case report. Urol Sci 2004;15.
18. Seki N, Mukai S, Gamachi A, Migita T, Maeda K, Ogata N. A case of bladder
pheochromocytoma. Urol Int 2001;66:57e60.
19. Al-Zahrani AA. Recurrent urinary bladder paraganglioma. Adv Urol 2010:
912125.
20. Young Jr WF. Paragangliomas: clinical overview. Ann N Y Acad Sci 2006;1073:
21e9.
21. Maddocks RA, Fagan Jr WT. Paraganglioma of bladder with recurrence ten
years later. Urology 1976;7:430e2.
